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Abstract
Background Sub-optimally controlled diabetes increases risks for adverse and costly complications. Self-management includ-
ing glucose monitoring, medication adherence, and exercise are key for optimal glycemic control, yet, poor self-management 
remains common.
Objective The main objective of the Trial to Incentivize Adherence for Diabetes (TRIAD) study was to determine the 
effectiveness of financial incentives in improving glycemic control among type 2 diabetes patients in Singapore, and to test 
whether process-based incentives tied to glucose monitoring, medication adherence, and physical activity are more effective 
than outcome-based incentives tied to achieving normal glucose readings.
Methods TRIAD is a randomized, controlled, multi-center superiority trial. A total of 240 participants who had at least one 
recent glycated hemoglobin (HbA1c) being 8.0% or more and on oral diabetes medication were recruited from two polyclin-
ics. They were block-randomized (blocking factor: current vs. new glucometer users) into the usual care plus (UC +) arm, 
process-based incentive arm, and outcome-based incentive arm in a 2:3:3 ratio. The primary outcome was the mean change 
in HbA1c at month 6 and was linearly regressed on binary variables indicating the intervention arms, baseline HbA1c levels, 
a binary variable indicating titration change, and other baseline characteristics.
Results Our findings show that the combined incentive arms trended toward better HbA1c than UC + , but the difference 
is estimated with great uncertainty (difference − 0.31; 95% confidence interval [CI] − 0.67 to 0.06). Lending credibility 
to this result, the proportion of participants who reduced their HbA1c is higher in the combined incentive arms relative to 
UC + (0.18; 95% CI 0.04, 0.31). We found a small improvement in process- relative to outcome-based incentives, but this was 
again estimated with great uncertainty (difference − 0.05; 95% CI − 0.42 to 0.31). Consistent with this improvement, process-
based incentives were more effective at improving weekly medication adherent days (0.64; 95% CI − 0.04 to 1.32), weekly 
physically active days (1.37; 95% CI 0.60–2.13), and quality of life (0.04; 95% CI 0.0–0.07) than outcome-based incentives.
Conclusion This study suggests that both incentive types may be part of a successful self-management strategy. Process-
based incentives can improve adherence to intermediary outcomes, while outcome-based incentives focus on glycemic 
control and are simpler to administer.
Supplementary Information The online version contains 
supplementary material available at https ://doi.org/10.1007/s4027 
1-020-00491 -y.
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1 Introduction
Sub-optimally controlled diabetes increases risks for a host 
of adverse and costly complications, including heart attacks, 
strokes, kidney failure, lower limb amputation(s), blind-
ness, and nerve damage [1]. There is a strong consensus 
that optimal glycemic control is essential to minimize risks 
for these complications [2]. Many studies have shown that 
careful self-management, including regular glucose moni-
toring, medication adherence, regular exercise, and weight 
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Key Points for Decision Makers 
A lack of diabetes self-management practices remains 
common.
This study highlights the challenges in achieving 
improvements in glycemic control and provides only 
limited evidence that incentives may be part of a suc-
cessful multicomponent intervention to improve glyce-
mic control and self-management.
More research is required to determine the strategy, size, 
and type of incentives that may cost-effectively improve 
self-monitoring and glycemic control among those with 
type 2 diabetes.
outcomes is expected to be a more cost-effective strategy 
than tying it to self-management processes, as incentives 
are only paid out upon success. However, outcome-based 
incentives might be less effective than process-based 
incentives if many people find the specified goals too chal-
lenging to make an effort to reach them and/or do not see 
enough of a direct link between changes in behavior and 
changes in the target of the incentives (i.e., overall glyce-
mic control) [27].
The aim of the Trial to Incentivize Adherence for Diabe-
tes (TRIAD) study was to test these competing approaches 
to incentives via a three-arm randomized controlled trial. 
The first arm, usual care plus (UC +), merely added moni-
toring devices to diabetes usual care (glucometer, medica-
tion tracker, and pedometer) to create a control group. The 
second arm applied a process-based strategy that tied incen-
tives to regular glucose monitoring, medication adherence, 
and physical activity. The third arm was outcome based and 
tied incentives solely to having self-monitored blood glucose 
readings in the acceptable range. We hypothesized that pro-
viding either form of incentive would be more effective than 
UC + in improving glycemic control. We did not hypothesize 
which incentive strategy would have the largest effect on 
glycemic control, as competing arguments can be made sup-
porting each strategy.
2  Methods
2.1  Study Design
A detailed description of the TRIAD study protocol has been 
published previously [28]. In brief, 240 participants were 
block-randomized (blocking factor: current vs. new glucom-
eter users) into the UC + , process-based incentives, and out-
come-based incentives arms in a 2:3:3 ratio. Our sample size 
was calculated to detect an effect size of 1.0% in glycated 
hemoglobin (HbA1c) at a 5% significance level. The study 
was registered on ClinicalTrials.gov (ID: NCT02224417). 
Written informed consent was obtained from all participants.
2.2  Participants
Participants were recruited from two polyclinics in Gey-
lang and Bedok estates in Singapore between February 
2015 and December 2017. The participant timeline is 
described in detail in Fig. 1. Recruited participants had 
sub-optimally controlled diabetes—defined as having at 
least one HbA1c within the last 6 months of 8.0% or more. 
Participants were on at least one oral diabetes medication 
control, supports optimal glycemic control [3–6], resulting 
in improved health outcomes and lower healthcare utiliza-
tion and costs, including a reduction in emergency depart-
ment visits and hospitalizations [7, 8]. Yet, poor self-man-
agement remains common [9, 10].
From a behavioral economics perspective, poor self-man-
agement is thought to partly arise from people’s bias towards 
the present. Indeed, the cost of self-management, primar-
ily in terms of time and effort, is immediate and certain, 
whereas the health benefits are distant and uncertain [11, 
12]. One strategy to address present bias and improve short-
term glycemic control and long-term health outcomes is to 
provide people with a near-term benefit, such as a financial 
incentive. Financial incentives, implemented either alone or 
as part of multi-component interventions, have been used 
in many health-related interventions in efforts to overcome 
present bias [13–23]. However, the literature provides little 
guidance on what objective one should tie the incentives 
to. In this study, we explored whether it is more effective to 
tie the incentives to intermediary processes supporting the 
desired outcome, or whether it is more effective to incentiv-
ize the outcome directly.
Process-based incentives focus on motivating near-term 
behaviors associated with optimal glycemic control, such 
as self-monitoring of blood glucose, with the underlying 
idea that incentivizing these behaviors can overcome peo-
ple’s present bias [24, 25]. However, the challenge with 
this approach is that individuals could engage in only a 
subset of behaviors such that overall glycemic control is 
not effectively improved [26]. An alternative approach is 
to focus on near-term health outcomes, such as having glu-
cose readings within the acceptable range. This approach 
also addresses present bias, while providing flexibility 
on how to attain the objective. Tying incentives to health 
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(had been for at least 3 months), were aged 21–70 years, 
were Singapore citizens or permanent residents, and were 
able to converse in English or Mandarin. Patients who 
were on insulin, were unable to take their oral medication 
independently, were pregnant, or had a physical condition 
that could be made worse with exercise were excluded 
from the study.
2.3  Randomization
Prior to recruitment, randomization numbers were gener-
ated by the principal investigator and the project coordinator 
(PC) using Stata 13.2. Participants were block-randomized 
into one of the three study arms in a ratio of 2:3:3 based on 
whether they were current glucometer users or not. The PC 
Fig. 1  Participant timeline
CRC administered screener quesonnaire.
Text messages were sent:
- 7 days aer Baseline
- 28 days aer Baseline
- 56 days aer Baseline
Month 3 assessment
- Data from the devices were downloaded from study devices and 
imported to study web system
- Incenves were calculated
- Study payments were made to parcipant
Text messages sent:
-28 days aer Month 3 assessment
-56 days aer Month 3 assessment
Month 6 assessment
- HbA1c test were taken
- Month 6 quesonnaires were administered
- Data from the devices were downloaded from study devices and 
imported to study web system
- Incenves were calculated
- Study payments were made to parcipant
Parcipants were randomized into UC+, Process and Outcome arms.
- Incenves were explained to process and outcome arm 
parcipants
- Study devices were issued to parcipants
- Study leaflets were given to study parcipants
CRC obtained wrien informed consent from all eligible parcipants.
For eligible parcipants with significant medical history or physical condion based on the 
screener, an approval to parcipate in the study was sought from an independent doctor.
Paents were referred to CRC by doctor or paents saw recruitment 
adversement and contacted CRC
Baseline assessment
- Baseline quesonnaires were administered
- HbA1c blood tests were taken
Legend:
CRC: Clinical Research 
Coordinator
UC+: Usual Care Plus
HbA1c: Glycated 
Hemoglobin
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and a witness external to the study enclosed the assignments 
in sequentially numbered, opaque, sealed randomization 
envelopes, which were handed over to the Clinical Research 
Coordinators (CRCs) at the polyclinics. Upon informed con-
sent, the CRCs drew the next sequential envelope based on 
the participant’s glucometer use status. The allocation was 
then revealed to both the CRC and participant. The study 
arm assignment was not revealed to the laboratory staff 
assessing the primary outcome (i.e., HbA1c).
2.4  Intervention
All participants received usual care, as per the SingHealth 
Polyclinics structured framework for diabetes patients, 
including information on the recommended guidelines on 
blood glucose monitoring, acceptable blood glucose range, 
medication adherence, and physical activity (see Fig. 2).
To tease out the independent effect of incentives, each 
participant, regardless of which arm they were assigned, 
received a TRUEresult™ glucometer to measure their 
blood glucose if they did not already have one, an eCAP™ 
to track their medication adherence, and a Fitbit Zip™ to 
monitor their physical activity. Participants also received 
regular arm-specific text messages (7, 28 and 56 days after 
the baseline visit and 28 and 56 days after the month 3 visit) 
to remind them to exercise regularly, take their medications 
as prescribed, and monitor their blood glucose regularly (see 
Fig. 3). Because of these additions to usual care, we called 
the control arm UC + .
The process-based incentive participants earned finan-
cial incentives contingent on meeting specified inter-
mediary health behaviors: 3.50 Singapore dollars (S$) 
(S$1 = US$0.74, as at 11 November 2020) weekly if they 
measured their blood glucose on three non-consecutive days 
each week, S$0.50 daily if they took their medication as 
prescribed, and S$1 daily if they completed 8000 steps as 
recorded by the Fitbit Zip™. The outcome-based incentive 
participants earned S$2 weekly if they had one pre-meal 
glucose reading within the acceptable range of 4–7 mmol/L 
(72–126 mg/dL), S$7 if they had two pre-meal glucose read-
ings within the acceptable range, or S$14 if they had three 
pre-meal glucose readings within the acceptable range in a 
week. The maximum amount of incentives that participants 
in the process and outcome arms could earn per week was 
S$14 (US$10.36). This is a relatively small amount but more 
than enough to offset the additional cost of buying test strips 
and lancets for three glucose measurements per week, which 
ranges from S$2.25 to S$5.52 (prices as of 11 November 
2020) depending on the glucometer brand and model. Par-
ticipants in the control arm did not receive any financial 
incentive but received a S$75 non-contingent payment at 
the end of month 6 for participating in the study. Incentives 
were paid out in the form of supermarket vouchers at month 
3 and month 6. The intervention lasted for 6 months, from 
March 2015 to June 2018. Although a longer post-incentive 
follow-up period was originally planned, due to the enact-
ment of a new regulation on human biomedical research, 
only a 6-month evaluation was possible.
2.5  Data Collection
Participants were assessed at baseline, month 3, and month 
6. At each assessment, information from their pedometer, 
medication tracker and glucometer were uploaded to the 
study website and participants’ HbA1c was recorded. Paper-
based survey questionnaires were also administered at base-
line and month 6. The baseline questionnaire assessed the 
socio-demographic characteristics of the participants. Both 
baseline and month 6 questionnaires included the European 
Quality of Life–5 Dimensions–5 Levels (EQ-5D-5L), Brief 
Illness Perception Questionnaire (BIPQ), Self-Monitoring 
of Blood Glucose (SMBG), and Beliefs about Medication 
Questionnaire (BMQ).
Fig. 2  Sample of the study leaflet on self-management
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2.6  Outcomes
The primary outcome was the mean change in HbA1c at 
month 6 from baseline. Secondary outcomes included mean 
number of glucose readings within the acceptable range 
(4–7 mmol/L), mean number of glucose readings (i.e., with a 
minimum of three non-consecutive testing days in a week as 
per SingHealth Polyclinics recommendation), mean number 
of medication adherent days (i.e., taking all the medication 
doses in a day within the pre-defined time windows, as veri-
fied by the eCAP™ medication tracker), and mean number 
of physically active days (i.e., logging at least 8000 steps 
per day on the Fitbit Zip™) on the last week of intervention.
Exploratory outcomes included the proportion of par-
ticipants whose oral medication was titrated up and/or who 
switched to another medication, including insulin, during the 
intervention, and mean changes from baseline in EQ-5D-5L, 
BIPQ, SMBG, and BMQ scores.
2.7  Statistical Analysis
All analyses were carried out as pre-specified in the study 
protocol and followed an intention-to-treat approach. As 
such, all missing data in both independent and dependent 
variables were filled using Markov chain Monte Carlo mul-
tiple imputation.
2.7.1  Primary Analyses
We first tested the effectiveness of financial incentives, 
either process or outcome based, in reducing HbA1c lev-
els. Change in HbA1c readings from baseline to month 6 
Fig. 3  Text messages sent to 
participants. CRC Clinical 
Research Coordinator, SMS 
short message service, SGD 
Singapore dollars, TRIAD Trial 
to Incentivize Adherence for 
Diabetes, UC + usual care plus
SMS Schedule to parcipants
ID
Time point
UC + Process Outcome
Week 1 1 1 1
Month 1 2-1 2-2 2-3
Month 2 3-1 3-2 3-3
Month 4 2-1 2-2 2-3
Month 5 3-1 3-2 3-3
Day 21 of each month where no step acvity is recorded 4 4 4
ID Text Message
1
Dear parcipant, many thanks for taking part in the TRIAD study. Please remember that regular 
physical acvity, taking medicaon as recommended and monitoring your glucose level will help 
manage your diabetes. For assistance, please contact (CRC name) at (CRC contact). 
2-1 Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will receive SGD15 for 
aending the Month 3 Visit. You will also receive SGD90 at the end of the study for recording your 
data and aending the Month 6 Visit. For assistance, please contact (CRC name) at  (CRC contact).
2-2
Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will earn SGD14 weekly 
for meeng all acvity, medicine-taking and glucose tesng goals. For assistance, please contact 
(CRC name) at (CRC contact).
2-3
Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will earn SGD14 weekly 
for meeng your glucose level goals. For assistance, please contact (CRC name) at (CRC contact).
3-1
Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will receive SGD90 at the 
end of the study for recording your data and aending the Month 6 Visit. For assistance, please 
contact (CRC name) at (CRC contact).
3-2
Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will earn SGD14 weekly 
for meeng all goals. For assistance, please contact (CRC name) at (CRC contact).
3-3
Dear TRIAD parcipant, please remember that regular physical acvity, taking medicaon as 
advised and glucose level monitoring will help manage your diabetes. You will earn SGD14 weekly 
for meeng your goals. For assistance, please contact (CRC name) at (CRC contact).
4 Dear TRIAD parcipant, A gentle reminder that if you have not yet synced your Fitbit you have 1 
week le to sync. If you wish you can sync at the Polyclinic, please contact (CRC name) at (CRC 
contact). Thank you. 
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was linearly regressed on a binary variable indicating par-
ticipation in the incentive arms, with UC as the reference 
category, baseline HbA1c readings, the interval (in days) 
between baseline and month 6 HbA1c test date, and base-
line characteristics, including gender, age, education level, 
employment status, income, EQ-5D-5L, BIPQ, SMBG, and 
BMQ scores, and number of comorbidities. The analysis was 
performed using an intention-to-treat approach.
To measure the difference in effectiveness between 
incentive strategies, we used the same model as above but 
restricted the sample to the participants in the incentive arms 
and changed the reference category of the binary variable to 
the process-incentive arm.
As sensitivity analyses, we ran a regression analysis car-
rying forward the last measured HbA1c level (baseline or 
month 3), and a regression with no imputation of the missing 
HbA1c observations.
2.7.2  Secondary Analyses
Using the same approach as for the primary analyses, we 
tested the effectiveness of financial incentives in improving 
treatment adherence as measured by the mean number of 
glucose readings within the acceptable range, mean number 
of glucose readings, mean number of medication-adherent 
days, and mean number of physically active days on the last 
week of the intervention. These were separately regressed 
against the same set of independent variables used in the 
primary analyses.
2.7.3  Exploratory Analyses
To test whether the intervention encouraged changes in 
medication adherence, we estimated separate logistic regres-
sions of binary variables indicating whether the participants 
had a titration/change of their oral medicine or whether they 
switched to insulin therapy during the intervention. We also 
ran separate linear regressions on the changes from baseline 
in EQ-5D-5L, BIPQ, SMBG, and BMQ scores at month 
6. For all models, the covariates were the binary variables 
indicating the incentive arms and the same baseline charac-
teristics used in the primary analyses.
We also analyzed the effect of potential moderators, 
including gender, age, language spoken, education, occupa-
tion, income, EQ-5D-5L, BIPQ, SMBG, and BMQ scores, 
and number of comorbidities on the change in HbA1c at 
month 6. To do so, the model used in the primary analy-
sis was extended by adding interaction terms (in separate 
regressions) between each potential moderator and the 
binary variables indicating study arms.
3  Results
A total of 1387 patients were assessed for eligibility (Fig. 4). 
Eight hundred and eighty-four (63.7%) were found eligible 
to participate. Among the eligible, 240 (27%) responded to 
the invitation to participate and were consented and rand-
omized into the three arms, 61 into UC + , 87 into the pro-
cess-based incentive arm, and 92 into the outcome-based 
incentive arm. Twenty-eight participants (11.7%) withdrew 
from the study before the month 6 assessment, while 14 
(5.8%) were discontinued due to insulin initiation. The pro-
portion of participants who were lost to follow-up, either 
due to insulin initiation or other reasons, is not statistically 
different across study arms (p value 0.71). A summary of 
missing observations is reported in Fig. 5. 
Baseline participant characteristics are shown in Table 1. 
On average, participants were 55 years old, had two children, 
and had a baseline HbA1c of 9.1%. Only 19% reported that 
their health was excellent or very good. Thirty-four percent 
reported that they were self-monitoring their blood glucose. 
There were no observed statistical differences in socio-demo-
graphic characteristics between the incentive and control arms.
Table 2 shows the estimated incremental effects of incen-
tives, either outcome or process based. The mean differ-
ence is in the hypothesized direction, a greater reduction 
in HbA1c (difference − 0.31; 95% confidence interval [CI] 
− 0.67 to 0.06) compared to UC + , but the difference is esti-
mated with great uncertainty (p value 0.11). Consistent with 
incentives having an effect, the proportion of participants 
who had any improvement in HbA1c is higher in the incen-
tive arms by 18% (95% CI 4–31) than in UC + . Incentive 
arm participants, on average, also had 0.32 more glucose 
readings within the acceptable range (out of three tests per 
week) (95% CI 0.07–0.57), had 0.40 more glucose read-
ings (out of three tests per week) (95% CI 0.04–0.76), were 
more adherent to their medication by 0.72 days (95% CI 
0.05–1.38), and were more physically active by 1.12 days 
(95% CI 0.38–1.86). Participants in the incentive arms also 
had higher treatment control scores by 0.62 (95% CI − 0.02 
to 1.26) compared to control group participants, but this 
result was also estimated with great uncertainty. Other out-
come and process measures showed no consistent trends and 
were associated with large CIs.
The incremental effects of outcome- compared to pro-
cess-based incentives are reported in Table 3. The difference 
in HbA1c between the process and outcome arms was small 
and estimated with great uncertainty (difference − 0.05; 95% 
CI − 0.42 to 0.31). This conclusion holds for the secondary 
outcomes considered: the proportion of participants who 
had any improvement in HbA1c (difference − 0.02; 95% 
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CI − 0.14 to 0.11), the mean number of glucose readings 
within the acceptable range (out of three tests per week) (dif-
ference 0.07; 95% CI − 0.21 to 0.34), and the mean number 
of glucose readings (out of three tests per week) (difference 
− 0.06; 95% CI − 0.45 to 0.32). The mean incentive payout 
on the last week of the intervention was also similar between 
the two arms (process = S$5.43 [95% CI 4.22–6.62] vs. out-
come = S$6.21 [95% CI 4.47–7.95]).
Lending some support to the hypothesis that process-
based incentives improve intermediate outcomes, out-
come-arm participants had fewer medication adherent days 
(difference − 0.64; 95% CI − 1.32 to 0.04) and were less 
physically active during the last week of the intervention 
(difference − 1.37 days; 95% CI − 2.13 to − 0.60), although 
these results were again estimated with great uncertainty. 
Further, self-reported EQ-5D-5L scores worsened among 
outcome-arm participants compared to process-arm partici-
pants (difference − 0.04; 95% CI − 0.07 to − 0.004). There 
were no clear differences between groups in the treatment 
control domain (“How much do you think your treatment 
can help your diabetes?”) or in the other exploratory out-
comes considered.
We tested the robustness of our primary and secondary 
outcome estimates using [1] regressions not controlling for 
Fig. 4  Participant flow diagram. 
UC + usual care plus
Follow-up
Allocation
47 (77.0%) Completed the 
study
 9 (14.8%) Withdrew
 5 (8.2%) Discontinued due 
to insulin initiation
76 (82.6%) Completed the 
study
11 (11.9%) Withdrew
  5 (5.4%) Discontinued 
due to insulin initiation 
75 (86.2%) Completed the 
study
 8 (9.2%) Withdrew
 4 (4.6%) Discontinued 
due to insulin initiation
61 (25.4%) UC+ 92 (38.3%) Outcome87 (36.25%) Process  
240 Randomized
Enrolment






Fig. 5  Missing observations. 
UC + usual care plus
Missing: 2 (2.3%) Missing: 1 (1.1%)Missing: 1 (1.6%)
Baseline
Month 6
UC + Process Outcome
Missing: 1 (1.1%)Missing: 0 (0%)Missing: 0 (0%)
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confounders, [2] last observation carried forward and [3] 
using a per protocol approach. Results from these estimation 
methods were similar to the reported estimates in Tables 2 
and 3. Lastly, we tested for a range of moderators for the 
incentive effect and found no clear signs of effect for any of 
those tested, although this may be due to a lack of statisti-
cal power for testing such hypotheses (please refer to Sup-
plementary Information Tables 1.1–1.3 and 2.1–2.3 in the 
supplementary electronic material).
Table 1  Participants’ baseline 
characteristics
BIPQ Brief Illness Perception Questionnaire, BMQ Beliefs about Medication Questionnaire, EQ-5D-5L 
European Quality of Life–5 Dimensions–5 Levels, HDB Housing and Development Board, HbA1c glycated 
hemoglobin, JTC Jurong Town Corporation, S$ Singapore dollars SMBQ Self-Monitoring of Blood Glu-
cose, UC + usual care plus
a Thirty-four participants had missing/don’t know/refused answers
All participants UC + arm Incentive arms
Process Outcome
(N = 240) (N = 61) (N = 87) (N = 92)
Socio-demographic characteristics
 Age, mean (SD) 55.23 (8.3) 54.8 (8.4) 54.7 (8.2) 56.1 (8.3)
 Gender, n (%)
  Male 130 (54.2) 35 (57.4) 49 (56.3) 46 (50.0)
  Female 110 (45.8) 26 (42.6) 38 (43.7) 46 (50.0)
 Highest level of education, n (%)
  No formal education/primary 41 (17.1) 10 (16.4) 14 (16.1) 17 (18.5)
  Secondary 105 (43.7) 26 (42.6) 35 (40.2) 44 (47.8)
  Post-secondary 94 (39.2) 25 (41.0) 38 (43.7) 31 (33.7)
 Ethnicity, n (%)
  Chinese 117 (48.8) 22 (36.1) 44 (50.6) 51 (55.4)
  Malay 60 (25.0) 18 (29.5) 16 (18.4) 26 (28.3)
  Indian/others 63 (26.3) 21 (34.4) 27 (31.0) 15 (16.3)
 Married, n (%) 175 (72.9) 45 (73.8) 64 (73.6) 66 (71.7)
 No. of children, mean (SD) 2.1 (1.3) 2.2 (1.1) 2.1 (1.4) 1. 9 (1.3)
 Housing type, n (%)
  HDB/JTC flat (1–3 room) 85 (35.4) 17 (27.9) 35 (40.2) 33 (35.9)
  HDB/JTC flat (4 room) 85 (35.4) 26 (42.6) 21 (24.1) 38 (41.3)
  HDB/JTC flat (5 room)/condominium/bun-
galow/semi-detached/terrace house
70 (29.2) 18 (29.5) 31 (35.6) 21 (22.8)
 Household’s average monthly income, n (%)
  No income/below S$2000 71 (29.6) 12 (19.7) 28 (32.2) 31 (33.7)
  S$2000–S$3999 58 (24.2) 18 (29.5) 19 (21.8) 21 (22.8)
  S$4000 and over 60 (25.0) 16 (26.2) 20 (23.0) 24 (26.1)
  Refused 51 (21.3) 15 (24.6) 20 (23.0) 16 (17.4)
 Currently employed, n (%) 143 (59.6) 34 (55.7) 58 (66.7) 51 (55.4)
 Self-monitoring of blood glucose 82 (34.2) 20 (32.8) 33 (37.9) 29 (31.5)
Primary outcome
 HbA1c reading, mean (SD) 9.1 (1.3) 9.1 (1.4) 9.0 (1.2) 9.3 (1.4)
Exploratory outcomes
 EQ-5D-5L, mean (SD) 0.91 (0.14) 0.89 (0.15) 0.92 (0.13) 0.92 (0.15)
 BIPQ total score, range 8–80, mean (SD) 38.7 (9.6) 38.4 (10.3) 37.8 (9.9) 39.9 (8.9)
 SMBQ score, range 6–54, mean (SD) 26.5 (4.7) 25.9 (4.5) 27.1 (4.5) 26.4 (4.9)
 BMQ General score 23.2 (4.5) 22.6 (4.2) 23.2 (4.8) 23.5 (4.4)
 Number of  comorbiditiesa 1.3 (0.9) 1.4 (0.96) 1.3 (0.86) 1.4 (0.90)
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4  Discussion
The first objective of this study was to quantify the effect of 
financial incentives on glycemic control among polyclinic 
patients with sub-optimally controlled diabetes. We found 
that financial incentives reduced HbA1c by 0.31 compared 
to a control group receiving usual care and monitoring 
devices. Even though this result was associated with a fairly 
large p value (p value 0.11), there are several reasons to 
suggest that incentives had an effect. First, we calculated an 
additional outcome for the proportion of participants who 
improved their baseline glycemic control at month 6 and 
found that 18% more participants improved their HbA1c 
in the incentive groups (p value 0.013). Moreover, we also 
found evidence consistent with the effectiveness of incen-
tives for the number of glucose readings within the accept-
able range (0.32), number of glucose readings (0.40), weekly 
medication adherent days (0.72), and weekly physically 
active days (1.12).
Our results are consistent with other studies that aimed 
to achieve a reduction in HbA1c through financial incen-
tives. These studies showed significant behavior changes, 
i.e., improvements in medication adherence, regular physi-
cal activity, and/or glucose monitoring but did not show 
clinically significant improvements in glycemic control [18, 
29–31], or had clinically significant improvements that were 
not statistically significant based on conventional p values 
[32, 33]. Overall, evidence suggests that financial incentives 
alone have a small to moderate effect on glucose control and, 
consequently, that a larger sample size than that used in our 
study is needed to confirm this effect.
A notable finding is that only 34% of the participants in 
our sample engaged in self-monitoring of blood glucose at 
baseline. The low rate of monitoring and lack of regular 
monitoring may be due to patients’ negative perception and 
attitude towards glucose self-monitoring. The discomfort 
associated with testing and potential frustration with high 
glucose readings could be some of the barriers to regular 
self-monitoring [34]. Cost could also be an additional bar-
rier as the approximate cost of glucose monitoring three 
times a week incurred by a patient ranges from S$2.25 to 
S$5.52 (prices as of 11 November 2020) depending on the 
glucometer brand and model. Despite the low level of glu-
cose monitoring at baseline, financial incentives were effec-
tive in increasing glucose monitoring. However, the glucose 
monitoring incentive may have inadvertently encouraged 
process-arm participants to overemphasize testing in lieu 
of behavior change. Several authors have noted that it is not 
Table 2  Estimated effects of the intervention by arms and the incremental effect of  incentivea (N = 240) Source: Author calculations using the 
data collected from the study
BIPQ Brief Illness Perception Questionnaire, BMQ Beliefs about Medication Questionnaire, CI confidence interval, EQ-5D-5L European Qual-
ity of Life–5 Dimensions–5 Levels, HbA1c glycated hemoglobin, SMBQ Self-Monitoring of Blood Glucose, UC + usual care plus
a Calculated as the difference in change from baseline at month 6 between intervention and control groups
Study arms Incremental effect of incen-
tive
UC+ Incentive Estimate [95% CI]
Primary outcome
 Mean change in HbA1c at month 6 − 0.73 − 1.04 − 0.31 [− 0.67 to 0.06]
Secondary outcomes
 Mean no. of glucose readings within acceptable range (out of 3 tests) during the last 
week of intervention
0.16 0.48 0.32 [0.07 to 0.57]
 Mean no. of glucose readings (out of 3 tests) during the last week of intervention 0.73 1.12 0.40 [0.04 to 0.76]
 Mean no. of medication adherent days during the last week of intervention 0.97 1.69 0.72 [0.05 to 1.38]
 Mean no. of physically active days during the last week of intervention 1.24 2.35 1.12 [0.38 to 1.86]
Exploratory outcomes
 Proportion of participants who titrated up their oral medication during the intervention 0.35 0.39 0.04 [− 0.1 to 0.18]
 Proportion of participants who switched to insulin treatment during the intervention 0.09 0.05 − 0.04 [− 0.12 to 0.04]
 Mean change in EQ-5D-5L at month 6  0.01 0.01 0.002 [− 0.03 to 0.04]
 Mean change in overall BIPQ score at month 6 − 1.59 − 1.91 − 0.32 [− 3.02 to 2.38]
 Mean change in BIPQ Treatment Control score at month 6 − 0.31 0.31 0.62 [− 0.02 to 1.26]
 Mean change in SMBG score at month 6 0.49 0.50 0.01 [− 0.12 to 0.13]
 Mean change in BMQ Specific score at month 6 − 0.35 0.33 0.68 [− 0.59 to 1.94]
Additional outcomes
 Proportion of participants who had improvement in HbA1c at month 6 0.64 0.81 0.18 [0.04 to 0.31]
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uncommon for people who are testing their blood glucose to 
be proficient at and feel confident in their ability to perform 
tests, but to not use the results to influence their diet and 
exercise choices [35–38].
Our results do not show any significant difference in 
effectiveness between process- and outcome-based incen-
tives on glycemic control. However, process-based incen-
tives were statistically significantly more effective at improv-
ing medication adherence and physical activity at the 10% 
and 5% level, respectively, behaviors which are necessary 
for good glycemic control. Furthermore, process-based 
incentives participants reported an increase in their qual-
ity of life compared to UC + and outcome-based incentives 
participants. This increase in perceived well-being could 
possibly be due to the reinforcing effect of incentives on 
healthy self-management behaviors such as increased physi-
cal activity [39]. While there was no difference in incentive 
payouts between incentive groups, process-group incentives 
took more time to administer in the context of this trial and 
required more monitoring devices.
Although our goal was to tease out the independent effec-
tiveness of process versus outcome incentives, it is likely 
that neither strategy is sufficient as a stand-alone interven-
tion. Our study coupled the incentives with technology (i.e., 
monitoring devices), reminders, and other program features. 
However, since those in the control group received these 
intervention components as an addition to usual care, we 
cannot state whether the combined intervention would have 
been more effective relative to usual care alone. This should 
be an area of future research. Future studies could also test 
incentivizing both processes and outcomes to see whether 
or not this approach is more effective than incentivizing just 
one or the other [18, 19, 40].
Our study has many strengths, including the rigorous 
trial design, but also several weaknesses. Our statistically 
insignificant HbA1c results may be due to the lack of power 
given by our sample size calculation. Our results may have 
been stronger if we recruited participants who had higher 
HbA1c values at baseline, as they have more ability to 
improve. However, that would have limited our ability to 
recruit the required number of participants in the time avail-
able. Another challenge was in using blood glucose as an 
outcome to be incentivized. The advantage of blood glu-
cose, over HbA1c, is that it is modifiable and measurable 
Table 3  Estimated effects of the intervention by incentive arms and the incremental effect of outcome-based  incentivea (N = 240) Source: Author 
calculations using the data collected from the study
BIPQ Brief Illness Perception Questionnaire, BMQ Beliefs about Medication Questionnaire, CI confidence interval, EQ-5D-5L European Qual-
ity of Life–5 Dimensions–5 Levels, HbA1c glycated hemoglobin, SMBQ Self-Monitoring of Blood Glucose
a Calculated as the difference in change from baseline at month 6 between that adherence outcome and process groups
Incentive arms Incremental effect of 
outcome-based vs. process-
based incentives
Process Outcome Estimate [95% CI]
Primary outcome
  Mean change in HbA1c at month 6 − 1.04 − 1.10 − 0.05 [− 0.42 to 0.31]
Secondary outcomes
 Mean no. of glucose readings within acceptable range (out of 3 tests) during the last 
week of intervention
0.44 0.51 0.07 [− 0.21 to 0.34]
 Mean no. of glucose readings (out of 3 tests) during the last week of intervention 1.20 1.14 − 0.06 [− 0.45 to 0.32]
 Mean no. of medication adherent days during the last week of intervention 2.02 1.38 − 0.64 [− 1.32 to 0.04]
 Mean no. of physically active days during the last week of intervention 3.12 1.76 − 1.37 [− 2.13 to −0.60]
 Mean incentive payout during the last week of intervention 5.43 6.21 0.79 [− 1.62 to 3.19]
 Mean time (in minutes) taken by the intervention during the last week of intervention 15.74 12.91 − 2.84 [− 4.84 to −0.83]
Exploratory outcomes
 Proportion of participants who titrated up their oral medication during the intervention 0.43 0.36 − 0.08 [− 0.22 to 0.07]
 Proportion of participants who switched to insulin treatment during the intervention 0.05 0.05 0.00 [− 0.07 to 0.07]
 Mean change in EQ-5D-5L at month 6 0.03 − 0.01 − 0.04 [− 0.07 to −0.004]
 Mean change in BIPQ at month 6 − 0.78 − 3.09 − 2.31 [− 4.92 to 0.31]
 Mean change in BIPQ Treatment Control score at month 6 0.35 0.51 0.16 [− 0.42 to 0.73]
 Mean change in SMBG score at month 6 0.49 0.51 0.02 [0.10 to 0.14]
 Mean change in BMQ Specific score at month 6 0.06 0.43 0.37 [− 0.90 to 1.64]
Additional outcomes
 Proportion of participants who had improvement in HbA1c at month 6 0.82 0.80 − 0.02 [− 0.14 to 0.11]
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in the near-term. However, intraday fluctuations in glucose 
readings suggest that an incentive scheme integrating blood 
glucose outcomes with HbA1c outcomes may better trans-
late into long-term glycemic control. Our results are also 
likely driven by the size and type of incentives offered [20, 
41]. This is a problem with all incentive-based studies. It 
is also important to consider in interpreting our results that 
our study participation rate is low. Only 27% of the eligible 
participants joined the study, thus our results may not be 
generalizable. Finally, we deviated from the protocol by not 
analyzing the changes from baseline in HbA1c at month 
12 and month 18 due to recent changes in the regulations 
on human biomedical research in Singapore that made it 
infeasible to collect information beyond the month 6 assess-
ment. A longer duration would have enabled us to observe 
the intervention’s full effect on HbA1c [42, 43].
5  Conclusion
Our results highlight the challenges in achieving improve-
ments in glycemic control, yet provide suggestive evidence 
that incentives may be part of a successful multicomponent 
intervention strategy [18, 20]. While there was no significant 
difference in effectiveness between process- and outcome-
based incentives, process-based incentives improved medi-
cation adherence, physical activity level, and quality of life. 
On the other hand, process-based incentives are potentially 
more costly to administer due to the number of devices they 
require. More research is needed to determine the most cost-
effective strategies for implementing incentives for manage-
ment of diabetes and other chronic diseases.
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